ClinicalTrials.gg
Enrolling by invitationNCT05645536Updated Oct 23, 2026

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

A Phase 3 interventional study of TOL2506 and Tamoxifen in Breast Cancer, sponsored by Tolmar Inc.. Enrolling by invitation at 46 sites in 6 countries. Open to participants aged 18 Years to 51 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Tolmar Inc. · Phase 3, Interventional, and Treatment

How we know · 10 judgments

Updated Oct 23, 20261 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years to 51 Years
Sex
All
01

Study summary

TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer. The TOL2506A-EXT study described here is a safety extension study to assess and collect long-term data on the ongoing safety and tolerability of TOL2506 in combination with tamoxifen or an AI for up to 4 years.

02

Conditions studied

  • Breast Cancer

Keywords

  • Ovarian Suppression
  • HR+
  • HER2-
  • Oncology
  • Premenopausal
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 250 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Tolmar Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 51 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Females:

  1. Completed Visit 9, Week 48 visit of TOL2506A study and is a candidate for continued endocrine therapy + ovarian suppression
  2. Able to understand the nature of this study and provide written prior to the participation in the trial
  3. Age 18 to 51 inclusive

Exclusion Criteria:

  • Females:

    1. (BMI) \< 18.00 kg/m2
    2. \< 12 months
    3. performance status ≥ 3
    4. Unacceptable hepatic function as determined by any of the following:

      1. (ALT) ≥ 2X (ULN)
      2. Aspartate aminotransferase (AST) ≥ 2X ULN
      3. ≥ 2X ULN
      4. Alkaline phosphatase ≥ 2X ULN
      5. Severe hepatic impairment ( Class C)
    5. Unacceptable renal function as determined by any of the following:

      1. Creatinine ≥ 3X ULN
      2. ≤ 30 mL/minute
      3. Creatinine clearance ≤ 60 mL/minute in subjects with bone density 1.5 standard deviations below the young adult normal mean
    6. Screening 12-lead demonstrating any of the following:

      1. Heart rate > 100 beats per minute (BPM)
      2. QRS > 120 msec
      3. (QTc) > 450 msec
      4. PR > 220 msec
    7. Use of any new medications known to prolong the QT/QTc interval
    8. Any new medical condition or psychiatric, addictive or other disorder that, in the opinion of the Investigator, may interfere with trial conduct or result in the subject being ineligible to continue treatment with TOL2506
    9. Concomitant use of medications that may impact subject safety including but not limited to:

      1. Oral or transdermal hormonal therapy
      2. Estrogen, progesterone, or androgens
      3. Hormonal
    10. Change in tolerability to TOL2506 that precludes continued treatment
    11. Sexually active with a male partner and not willing to use at least 2 non-hormonal contraceptive methods throughout the study
    12. Is of with a positive urine pregnancy test at Screening

Males:

Inclusion Criteria:

  1. Completed Visit 9, Week 48 visit of TOL2506A study and is a candidate for continued endocrine + GnRH agonist therapy
  2. Able to understand the investigational nature of this study and provide written informed consent prior to participation in the trial

Males:

Exclusion Criteria:

  1. BMI \< 18.00 kg/m2
  2. Life expectancy \< 12 months
  3. ECOG performance status ≥ 3
  4. Unacceptable hepatic function as determined by any of the following:

    1. ALT ≥ 2X ULN
    2. AST ≥ 2X ULN
    3. Bilirubin ≥ 2X ULN
    4. Alkaline phosphatase ≥ 2X ULN
    5. Severe hepatic impairment (Child-Pugh Class C)
  5. Unacceptable renal function as determined by any of the following:

    1. Creatinine ≥ 3X ULN
    2. Creatinine clearance ≤ 30 mL/minute
    3. Creatinine clearance ≤ 60 mL/minute in subjects with bone density 1.5 standard deviations below the young adult normal mean
  6. Screening 12-lead ECG demonstrating any of the following:

    1. HR > 100 BPM
    2. QRS > 120 msec
    3. QTc > 450 msec
    4. PR > 220 msec
  7. Use of any new medications known to prolong the QT/QTc interval
  8. Any new medical condition or psychiatric, addictive or other disorder that, in the opinion of the Investigator, may interfere with trial conduct or result in the subject being ineligible to continue treatment with TOL2506
  9. Concomitant use of medications that may impact subject safety including but not limited to oral or transdermal hormonal therapy
  10. Change in tolerability to TOL2506 that precludes continued treatment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    TOL2506

    TOL2506 in combination with standard endocrine therapy (Tamoxifen \& Aromatase Inhibitors)

    Drug: TOL2506 · Drug: Tamoxifen · Drug: Letrozole tablets · Drug: Anastrozole Tablets · Drug: Exemestane Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. The occurrences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 4 years from enrolling in study

07

Study locations

46 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Mar 2030, 87 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 87 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartActual
Dec 28, 2022
Primary completionEst.
Mar 2030
CompletionEst.
Mar 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • HCG Manavata Cancer Centre · Nashik, India
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site removed
    Show 1 removed
    • HCG Manavata Cancer Centre · Nashik, India

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05645536
Lead sponsor
Tolmar Inc.
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Dec 28, 2022
Primary completion
Mar 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion